ROCKVILLE, Md.--(BUSINESS WIRE)--Sequella, Inc., a clinical-stage pharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it received a $3.8 million 5-year R01 grant from the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) to identify and develop new ethylenediamine-based antibiotics for Clostridium difficile, an emerging infectious pathogen causing life-threatening gastrointestinal disease.
